Mogwai, your scenario description (price action foretelling events) seemed to have worked again for SPPI. They announced this morning getting a CRL for Evomela.
Thanks, Sam, for the numbers. To this point, the FDA has stifled the Rx-Omega 3 market, and nearly killed Amarin in the process. Expect Amarin's fortunes will soon change for the better as a result of a possible 1A settlement and upcoming R-It interim look.
Once again, the weekly scripts shows that Vascepa is not gaining traction like it should.
Amarin Management hopefully has alternative plans, other than dilution, to keep the company afloat before the REDUCE-IT results are finally available because the revenue from Vascepa sales apparently is not going to do it.